Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes
about
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesCommon deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast.Sideroblastic anaemias.Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome?Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.Gene expression profiling in the myelodysplastic syndromes.Clinical relevance of cytogenetics in myelodysplastic syndromes.FISH panels for hematologic malignancies.Genetic and epigenetic alterations in myelodysplastic syndrome.Closing in on the pathogenesis of the 5q- syndrome.Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome.Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia.Cytogenetics findings in a histiocytic sarcoma case.Mitochondrial DNA variations in myelodysplastic syndrome.Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop.Protein 4.1 deficiency and deletion of chromosome 20q are associated with acquired elliptocytosis in myelodysplastic syndrome.Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).Trisomy 8 is the most frequent cytogenetic abnormality in de novo myelodysplastic syndrome in China.DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients.World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome.Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes
P2860
Q26778754-789F1EE1-4418-427F-AA95-69B9CF391432Q30157922-50F591CC-EB2E-4EB6-8077-F2D80E0D5E48Q33405487-FAED0781-29A0-4094-A576-F06D48E54872Q33651786-F90C2F16-203F-45C7-B1F9-35EF14BD81C2Q34556996-E783F82C-7F6C-4FA3-B9A3-60C06B52BD84Q35020669-E1EF513C-5028-4844-8052-6F4F96FAB36BQ35162458-719EE7BC-5742-4695-A2D2-0E5B54E25179Q35175273-90E756F3-4785-4D84-BFD6-D9EF344E65C5Q35844148-A0F289A2-23BD-4064-8A2E-02D87FB421CAQ36221521-AD350B88-61E2-44CD-B068-F861C6FC150FQ36721793-2E510FD1-D006-4CFD-9C5C-751C8B05912CQ37000296-E8656350-F7E0-4BFD-ABE0-329EA7DE7752Q37000299-B329A396-E784-4077-8F5B-AE75079024D3Q37752361-22F7437F-E1BB-4495-B22E-B0767442775CQ38195796-E9FF973B-541A-4DB7-AF16-8DB45610AF57Q38233492-063FD7BC-0F0E-4EC4-9913-F9F78825A701Q38289512-A1E82A91-0E10-4933-80EB-72C05E4CCC1EQ40551803-F5382AD0-581D-4765-B9C3-BDDD496B4E4CQ40555529-5EC8C09E-E450-4F7E-BF5C-E7A701A4CBA4Q40604775-526BB710-8082-4D48-BA72-95E0F6D1C780Q41609451-58BC0A45-21FE-428D-8877-7726EE9887FAQ42278852-0D2283FD-A9F1-4A49-B4C0-8A6ABF7B5B16Q43926326-D4D91649-CF6F-45B2-85B1-1FB7BE2EAC5DQ44003370-D5F26946-619E-4FBA-B2EE-1C8E2B96CCA3Q44738342-7759A50B-A2C5-4E0C-95FC-CFB98360F8CBQ46727255-C3F03C5B-F9BF-4063-8870-4D8DDEB3FB7FQ47217804-9C805D26-CB99-4139-819C-605A59E5371FQ47601605-781C1339-BC04-4A15-81A6-CC2F0633F495Q52777531-C3B633A5-8764-4854-9622-B08FBE2747EDQ53272763-FC9CD4C8-B57F-44D3-8CA2-C024627C97ABQ53298488-ACE563F4-8AAD-41EA-B800-F540462AA5A3Q53561569-24D95E76-8DAA-4B4D-90F0-636EDA6E5E6BQ54222794-1C8C499D-6C33-43E7-A639-6108C091D794Q58010106-DC0364E4-5F7D-4FD0-B942-579E08ECEEF9
P2860
Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Incidence, characterization an ...... mary myelodysplastic syndromes
@ast
Incidence, characterization an ...... mary myelodysplastic syndromes
@en
type
label
Incidence, characterization an ...... mary myelodysplastic syndromes
@ast
Incidence, characterization an ...... mary myelodysplastic syndromes
@en
prefLabel
Incidence, characterization an ...... mary myelodysplastic syndromes
@ast
Incidence, characterization an ...... mary myelodysplastic syndromes
@en
P2093
P2860
P1476
Incidence, characterization an ...... mary myelodysplastic syndromes
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.2000.01868.X
P407
P577
2000-02-01T00:00:00Z